BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Study to Assess Safety of Nivolumab in Routine Oncology Practice in China
- Conditions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3102
- Registration Number
- NCT04825873
- Locations
- 🇨🇳
Local Institution, Shanghai, Shanghai, China
A Study of Treatment Patterns and Clinical Outcomes of Psoriasis in Japan
- Conditions
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 114
- Registration Number
- NCT04826536
- Locations
- 🇯🇵
Local Institution, Minato-ku, Tokyo, Japan
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 216
- Registration Number
- NCT04817007
- Locations
- 🇷🇴
Local Institution - 0052, Bucuresti, Cluj, Romania
🇷🇴Local Institution - 0083, Bucuresti, Romania
🇷🇴Local Institution - 0051, Cluj, Romania
A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 632
- Registration Number
- NCT04810078
- Locations
- 🇹🇷
Local Institution, Izmir, Turkey
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Local Institution - 0088, West Reading, Pennsylvania, United States
A Study in Participants With First-Line Nivolumab Plus Ipilimumb Therapy Combined With Two Cycles of Chemotherapy for Metastatic Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 825
- Registration Number
- NCT04794010
- Locations
- 🇩🇪
Local Institution - 0001, Leipzig, Germany
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 153
- Registration Number
- NCT04772079
- Locations
- 🇧🇷
Local Institution - 0083, Rio de Janeiro, Brazil
🇧🇷Local Institution - 0067, São Paulo, Brazil
🇨🇦Dermatology Research Institute, Calgary, Alberta, Canada
A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnT
- Conditions
- Interventions
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 30
- Registration Number
- NCT04766892
- Locations
- 🇺🇸
Local Institution - 0014, Miami, Florida, United States
🇺🇸Local Institution - 0011, Tucson, Arizona, United States
🇺🇸Local Institution - 0005, Los Angeles, California, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-963272 in Participants With Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT04766476
- Locations
- 🇺🇸
Arizona Liver Health - Tucson, Tucson, Arizona, United States
🇺🇸Pinnacle Clinical Research - Austin, Austin, Texas, United States
🇺🇸Local Institution, San Antonio, Texas, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986308 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-02-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 46
- Registration Number
- NCT04763226
- Locations
- 🇺🇸
Local Institution - 0001, Lenexa, Kansas, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of BMS-986326 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 88
- Registration Number
- NCT04736134
- Locations
- 🇩🇪
Local Institution - 0001, Berlin, Germany